Fameglow Holdings Limited (“FAMEGLOW”, HKEX: 03774; formerly GEM: 8603) has received in-principle approval from Hong Kong Exchanges and Clearing Limited to transfer its listing from GEM to the Main Board under Chapter 9B of the Listing Rules. Trading on GEM will cease after 29 June 2026, with Main Board dealings to commence at 09:00 on 30 June 2026.

Key listing metrics • Market capitalisation (volume-weighted average over the relevant 250 trading-day period): approximately HK$3.05 billion, well above the HK$500.00 million threshold required under Main Board Rule 8.09(2). • Liquidity test satisfied: at least 50 % of trading days in the relevant period recorded daily turnover ≥ HK$50,000. • Public float on the Latest Practicable Date (17 June 2026): 43.07 % of issued shares, surpassing the 25 % requirement; free-float market value c.HK$3.98 billion. • Largest shareholder Equal Joy Holdings Limited (controlled by Chairman Mr Yip Chun Kwok Danny MH and CEO Ms Fu Chi Ching) holds 56.93 % of issued shares.

Strategic rationale Management expects Main Board status to: 1. Enhance corporate profile and international visibility. 2. Broaden access to institutional investors and diversify the shareholder base. 3. Improve financing flexibility and optimise capital structure.

Operational expansion • Medical-aesthetic network expanded from 6 centres at FY23/24 year-start to 16 by FY25/26 year-end, spanning Hong Kong Island, Kowloon, New Territories and Macau. • Active customer base grew from ~13,000 in FY24 to ~24,000 in FY26; average actual spending per customer rose from HK$19,000 to HK$25,000 over the same period. • Eight new sub-brands introduced since FY24 to target differentiated demographics, including “Angus’ Beauty Concept”, “LaserKool”, “Face It” and “MediHair”.

Financial performance (year ended 31 March, HK$ million) • Revenue: 2024 – 299.36; 2025 – 435.27; 2026 – 589.79. ‑ Two-year revenue growth: 96.99 % (approx. 40 % CAGR). • Gross profit (revenue minus cost of inventories & consumables): 2024 – 260.89; 2025 – 388.81; 2026 – 527.78. Gross margin improved to 89.5 % in FY26 (FY24: 87.2 %). • Profit attributable to shareholders: 2024 – 40.75; 2025 – 45.73; 2026 – 54.64. ‑ Net margin compressed to 9.3 % in FY26 from 13.6 % in FY24 amid rapid expansion. • Net assets: 2024 – 60.25; 2025 – 106.09; 2026 – 207.06, bolstered by HK$46.70 million equity placement (18.92 million new shares at HK$2.61 each) completed on 5 December 2025. • Net current position swung from a liability of HK$39.81 million (FY25) to an asset of HK$11.96 million (FY26) as cash rose to HK$110.69 million.

Capital structure & options • Total issued shares: 818.92 million. • Share option scheme capacity: 80.00 million shares remain ungranted; scheme will transition to Main Board Chapter 17 regime upon listing transfer.

Compliance status • All GEM Listing Rule obligations fulfilled; no material regulatory breaches reported during the three-year track record period. • Applications for Private Healthcare Facilities Ordinance clinic licences submitted; currently under Department of Health review.

Trading logistics • Board lot: 1,000 shares; trading currency: HKD. Existing share certificates remain valid post-transfer.

Investors are advised to exercise caution when dealing in FAMEGLOW shares ahead of the listing migration.